Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,883,535 papers from all fields of science
Search
Sign In
Create Free Account
linifanib
An orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Linifanib inhibits members of the vascular…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Narrower (1)
ABT-869
NCIt Antineoplastic Agent Terminology
Receptor Tyrosine Kinase Inhibition
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Linifanib With Chemotherapy Improves PFS in NSCLC
D. Levitan
2015
Corpus ID: 132502037
Adding linifanib to a carboplatin/paclitaxel regimen improved progression-free survival over placebo in advanced non-squamous…
Expand
2015
2015
Linifanib Fails to Improve Survival in Hepatocellular Cancer
D. Ilson
2015
Corpus ID: 77108037
Sorafenib, a multitargeted tyrosine kinase inhibitor, is the standard therapy for advanced hepatocellular cancer, but it has only…
Expand
2013
2013
Synthesis of receptor tyrosine kinase inhibitors linifanib
Li Song
2013
Corpus ID: 101891888
The synthesis of linifanib,a receptor tyrosine kinase inhibitor,has been accomplished via 5 steps according to the literature…
Expand
2012
2012
Synthesis of antineoplastic agent linifanib
Gong Ping
2012
Corpus ID: 99884859
Linifanib(ABT-869),a novel potent and selective inhibitor of the VEGF and PDGF platelet-derived growth factor families of RTKs…
Expand
2010
2010
Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure.
N. Tannir
,
Y. Wong
,
+7 authors
D. Michaelson
2010
Corpus ID: 73859419
4527 Background: Linifanib (ABT-869) is a potent inhibitor of VEGF and PDGF receptor tyrosine kinases. Phase I study results…
Expand
2010
2010
Linifanib treatment in patients with non-small cell lung cancer (NSCLC): Phase II results.
R. Soo
,
G. Goss
,
+7 authors
E. Tan
2010
Corpus ID: 73860400
7590 Background: Linifanib (ABT-869), a novel orally active VEGF/PDGF RTK inhibitor, had single-agent activity in pts with…
Expand
2010
2010
Extended linifanib therapy in patients with advanced solid tumors in a phase I trial.
B. Goh
,
C. Wong
,
+4 authors
R. Soo
2010
Corpus ID: 78584147
3053 Background: Linifanib (ABT-869) is an orally bioavailable, potent, selective VEGF and PDGF RTK inhibitor. Activity was…
Expand
2010
2010
Total lesion glycolysis and FDG SUV as early readouts of tumor response to Linifanib (ABT-869) in SCID mice with HT1080 xenografts
Yumin Zhang
,
Todd B. Cole
,
+6 authors
G. Fox
2010
Corpus ID: 73897334
2010
2010
Gateways to clinical trials.
A. Tomillero
,
M. A. Moral
Methods and Findings in Experimental and Clinical…
2010
Corpus ID: 43025264
(-)-Epigallocatechin gallate, Abafungin, ACE-031, Adapalene/benzoyl peroxide, AE-37, Aflibercept, AGS-003, Albiglutide…
Expand
2009
2009
Abstract B53: Assessment of the effect of food on the oral bioavailability and assessment of diurnal variation in the pharmacokinetics of linifanib
N. Gupta
,
Z. Yan
,
P. LoRusso
,
J. L. Ricker
,
D. Carlson
,
R. Pradhan
2009
Corpus ID: 85436490
Background: Linifanib (ABT‐869) is a novel orally active and selective inhibitor of vascular endothelial growth factor and…
Expand